Samsung Biologics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	4,814,000	4,556,972	3,497,146	3,694,589	3,001,295	1,568,007
Other Revenue	-	-0	-0	-	-0	-
Revenue	4,814,000	4,556,972	3,497,146	3,694,589	3,001,295	1,568,007
Revenue Growth (YoY)	-1.73%	30.30%	-5.34%	23.10%	91.41%	34.62%
Cost of Revenue	2,159,000	2,056,131	1,798,093	1,900,080	1,540,526	844,657
Gross Profit	2,655,000	2,500,841	1,699,053	1,794,509	1,460,769	723,350
Selling, General & Admin	434,000	357,259	313,046	535,421	380,456	169,630
Research & Development	-	37,181	36,711	81,588	45,884	954.22
Amortization of Goodwill & Intangibles	-	13,797	10,948	9,977	7,700	4,572
Other Operating Expenses	-	5,970	4,688	10,339	7,448	1,804
Operating Expenses	434,000	431,620	377,686	680,829	477,142	186,040
Operating Income	2,221,000	2,069,221	1,321,366	1,113,680	983,627	537,309
Interest Expense	-	-29,171	-34,123	-81,596	-64,064	-14,707
Interest & Investment Income	-	46,034	54,404	95,650	53,293	9,656
Earnings From Equity Investments	-	43,085	2,659	-499.42	27,260	13,853
Currency Exchange Gain (Loss)	-	-7,447	41,832	-11,186	-63,503	17,874
Other Non Operating Income (Expenses)	100,000	2,352	1,361	2,652	2,347	4,494
EBT Excluding Unusual Items	2,321,000	2,124,074	1,387,500	1,118,701	938,960	568,479
Gain (Loss) on Sale of Investments	-	-	-	5,152	72,653	269.12
Gain (Loss) on Sale of Assets	-	-5,443	-1,949	-3,866	-2,588	-7,466
Asset Writedown	-	-	-682.1	-	-	-
Pretax Income	2,321,000	2,118,631	1,384,869	1,119,987	1,009,025	561,283
Income Tax Expense	569,000	504,301	344,567	262,296	210,968	167,693
Earnings From Continuing Operations	1,752,000	1,614,330	1,040,302	857,691	798,056	393,589
Earnings From Discontinued Operations	170,000	170,022	43,014	-	-	-
Net Income to Company	1,922,000	1,784,352	1,083,316	857,691	798,056	393,589
Net Income	1,922,000	1,784,352	1,083,316	857,691	798,056	393,589
Net Income to Common	1,922,000	1,784,352	1,083,316	857,691	798,056	393,589
Net Income Growth	50.21%	64.71%	26.31%	7.47%	102.76%	63.33%
Shares Outstanding (Basic)	-	67	71	46	45	43
Shares Outstanding (Diluted)	-	67	71	46	45	43
Shares Change (YoY)	-	-5.85%	53.75%	1.95%	5.51%	-
EPS (Basic)	-	26628.00	15221.00	18528.27	17592.79	9146.19
EPS (Diluted)	-	26628.00	15221.00	18528.27	17577.11	9146.19
EPS Growth	-	74.94%	-17.85%	5.41%	92.18%	63.33%
Free Cash Flow	-	856,067	355,682	671,158	-3,792	48,343
Free Cash Flow Per Share	-	12775.14	4997.47	14498.68	-83.52	1123.38
Gross Margin	55.15%	54.88%	48.58%	48.57%	48.67%	46.13%
Operating Margin	46.14%	45.41%	37.78%	30.14%	32.77%	34.27%
Profit Margin	39.92%	39.16%	30.98%	23.21%	26.59%	25.10%
Free Cash Flow Margin	-	18.79%	10.17%	18.17%	-0.13%	3.08%
EBITDA	-	2,702,858	1,920,468	1,603,462	1,291,892	699,098
EBITDA Margin	-	59.31%	54.92%	43.40%	43.04%	44.59%
D&A For EBITDA	628,646	633,637	599,101	489,782	308,264	161,789
EBIT	2,221,000	2,069,221	1,321,366	1,113,680	983,627	537,309
EBIT Margin	46.14%	45.41%	37.78%	30.14%	32.77%	34.27%
Effective Tax Rate	24.52%	23.80%	24.88%	23.42%	20.91%	29.88%
Advertising Expenses	-	6,615	7,180	11,916	8,829	5,349

Source: S&P Global Market Intelligence. Standard template. Financial Sources.